ArticleIJID regions2025
Fifteen years of tuberculosis and HIV diagnostic services in Brazil: disruption, regional disparities, and recovery before, during, and after the COVID-19 pandemic.
Article in IJID regions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This study analyzes fifteen years of nationwide trends and regional disparities in tuberculosis (TB) and HIV diagnostics in Brazil, examining the impacts of the COVID-19 pandemic and the uneven recovery of diagnostic services across different regions. Methods: This nationwide ecological study analyzed monthly data on TB and HIV diagnostic tests performed in Brazil from 2010 to 2024, utilizing real-world data. Temporal trends and interrupted time-series analyses evaluated the immediate and progressive effects of the COVID-19 pandemic. Spatial patterns and autocorrelation were explored using bivariate Moran's I and Kernel density estimation. Results: Results showed significant abrupt declines during the COVID-19 pandemic for smear microscopy (-16.4%), culture (-21.4%), and HIV (-16.2%). Post-pandemic, Xpert MTB/RIF showed the highest monthly increase (+3.8%; 95% confidence interval: 2.9-4.7), while smear microscopy declined (-1.2%; 95% confidence interval: -2.0 to -0.5). Spatial analysis revealed pronounced regional heterogeneity, with Northern and Northeastern municipalities facing the greatest disruptions. The Xpert MTB/RIF test demonstrated greater resilience, with evident growth in its distribution and implementation over time. However, this increase resulted in a decrease in the conduction of smear microscopy tests and highlighted territorial disparities, since only 167 municipalities (3%) have Xpert MTB/RIF assays, mainly in the Southeast. Conclusions: COVID-19 significantly disrupted traditional TB and HIV diagnostics in Brazil, while there was an evident increase and resilience of Xpert MTB/RIF, reducing the use of smear microscopy tests. Policy efforts should prioritize the equitable expansion of molecular diagnostic technologies across all regions. This approach will improve early TB detection and drug resistance testing, thereby reducing diagnostic disparities and strengthening health system resilience toward achieving the End TB Strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.